ArticleClinical pharmacokinetics2024

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.

Joseph Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.